News Daily News New on the Scene Nonstatin Drugs: Experts Provide Guidance Caitlin E. Cox August 31, 2022
News Daily News New USPSTF Statin Guidance: Familiar Advice, Some Holes to Fill Shelley Wood August 23, 2022
News Features Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD? Michael O'Riordan August 15, 2022
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Daily News PCI and CABG Are Complementary Options for Left Main CAD, Say Experts Michael O'Riordan April 27, 2022
News Conference News ACC 2022 No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3 Michael O'Riordan April 13, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022
News Daily News More Evidence Links Breast Arterial Calcification and CVD Risk L.A. McKeown March 15, 2022
News Daily News Skipping Low-Value Cardiovascular Care Could Save Billions: AHA Michael O'Riordan March 01, 2022
News Daily News Fewer Diabetic Complications Seen When NOACs Given for AF L.A. McKeown February 22, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Daily News As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control Caitlin E. Cox January 10, 2022
News Daily News Black Patients With Chest Pain Differ From Whites, but Risks Are Similar Michael O'Riordan December 23, 2021
News Features FFR’s Future: Negative Trials Spur Debate Over Technology’s Role Michael O'Riordan December 23, 2021